

Date: August 17, 2020

Re: 340B Contract Pharmacy Pricing

Dear Valued Partner,

AstraZeneca to date has processed chargebacks associated with Contract Pharmacy arrangements consistent with the approach proposed in the Health Resources and Services Administration's ("HRSA") April 2010 guidance. Beginning on October 1, 2020, AstraZeneca plans to adjust this approach such that AstraZeneca only will process 340B pricing through a single Contract Pharmacy site for those Covered Entities that do not maintain their own on-site dispensing pharmacy.

To implement this new approach, AstraZeneca will stop processing 340B chargebacks for all Contract Pharmacy arrangements effective October 1, 2020. Any 340B Covered Entity that does not have an out-patient, on-site dispensing pharmacy should contact AstraZeneca to arrange for a Contract Pharmacy of its choice to be eligible to receive 340B pricing on behalf of the Covered Entity. To initiate this process, please contact <u>Membership@AstraZeneca.com</u>.

Pricing will be honored on all chargeback invoices prior to this date consistent with AstraZeneca's historic approach, but AstraZeneca asks for the removal of Contract Pharmacy eligibility prior to or by the end of business September 30, 2020.

For additional information or questions, please contact your AstraZeneca Account Director.

Sincerely,

DocuSigned by: Odaho Carron

Odalys Caprisecca Executive Director, Strategic Pricing & Operations